11/2/2011 | BK | Teva borrows approximately $8.5 billion during third-quarter 2011
|
10/14/2011 | CV | Cephalon's 2.5%, 2% notes convertible into cash following Teva merger
|
8/22/2011 | CV | Cephalon announces expected make-whole conversion amounts for notes
|
5/2/2011 | CVEMIG | Teva plans to use cash, bonds to acquire Cephalon for $6.8 billion
|
5/2/2011 | CV | Market Commentary: Cephalon adds outright, flat on hedge after Teva bid; Teva adds too; International Coal up
|
4/4/2011 | CV | Market Commentary: Horizon Lines takes another leg down; Life Technologies slips; Dendreon up; Meritor steady
|
4/1/2011 | CV | Market Commentary: New A123 slightly higher outright; Ramco slips below par; Meritor lower after cutting outlook
|
3/31/2011 | CV | Market Commentary: Greenbrier expands on debut; Ramco-Gershenson to price; Dendreon in line on drug news
|
3/30/2011 | CV | Market Commentary: Cephalon comes in on hedge after Valeant bid; new InterDigital up; Greenbrier adds in gray
|
3/14/2011 | CV | Market Commentary: USEC drops dollar neutral on Japan's nuclear crisis; Chesapeake up; Illumina, RAIT on tap
|
2/15/2011 | CV | Market Commentary: Prospect Capital trades up after pricing another $150 million convertible; Cephalon steady
|
8/13/2010 | CV | Market Commentary: PDL BioPharma falls 3 points outright; Qwest active on extended tender; Cephalon improves
|
7/21/2010 | CV | Market Commentary: Apache up a little in the gray; Genco quiet ahead of pricing; United Rentals, Cephalon add
|
6/28/2010 | CV | Market Commentary: Convertibles mixed on light volume; Navistar better; ProLogis down in line; Cephalon adds
|
6/1/2010 | CVLM | Cephalon calls its zero-coupon putable convertibles due 2033 at 100.25
|
4/9/2010 | CV | Market Commentary: Convertibles action crimped by low vol., vacations; Cephalon, Human Genome gain; Ford off
|
3/2/2010 | CV | Market Commentary: Newmont falls; Human Genome up on earnings, health care names bid higher; Annaly sells add-on
|
2/12/2010 | CV | Cephalon's 2% convertible notes, 0% convertibles are now convertible
|
12/31/2009 | CV | Outlook 2010: U.S. convertible secondary market set for 'milder' year after stellar 2009 returns
|
12/3/2009 | CV | Market Commentary: Medtronic still active; CompuCredit sinks on dividend news; bank preferreds show gains
|
12/1/2009 | CV | Market Commentary: Convertibles action revives; gold names in focus; Energy XXI, Sino-Forest launch new deals
|
11/24/2009 | CV | Market Commentary: Medtronic above par after earnings beat; Jefferies sinks; Cephalon rebounds after weakness
|
11/23/2009 | CV | Market Commentary: Cephalon trades mixed on disappointing drug study news; Tyson slips; TRW Automotive adds
|
10/27/2009 | CV | Market Commentary: Convertibles mostly weaker; Gaylord drops below 90; Ferro down 2.5 points; ProLogis gains
|
7/8/2009 | CV | Market Commentary: Amgen trades actively on positive trial news; Equinix dips but pares losses; Vale edges up
|
6/3/2009 | CV | Market Commentary: Convertibles quiet as players eye JetBlue, Biovail, Steel Dynamics; Cephalon, Human Genome up
|
5/22/2009 | CV | Cephalon greenshoe exercised, lifts 2.5% convertibles to $500 million
|
5/21/2009 | CV | New Issue: Cephalon prices upsized $435 million five-year convertibles to yield 2.5%, up 15%
|
5/21/2009 | CV | Market Commentary: Cephalon adds despite 'tough environment'; Hertz, Saks, Regions Financial slip on first day
|
5/20/2009 | CVHY | Cephalon files automatic stock, debt, convertibles, warrants shelf
|
5/20/2009 | CV | Cephalon $350 million five-year convertibles to yield 2.5%-3%, up 10%-15%
|
5/20/2009 | CV | Market Commentary: FPL trades steady to slightly lower on debut; Hertz gains in gray; Cephalon launches deal
|
5/6/2009 | CV | Cephalon lacks cash to fund all 2%, 0% convertibles if converted
|
3/17/2009 | CV | Market Commentary: Alcoa up in gray, markets expects bigger, repriced deal; Citi slips, seen cheap; Johnson Controls hold firm
|
11/26/2008 | CV | Market Commentary: Convertibles steady to higher in line with stocks; Chesapeake Energy gains; Ford, Cephalon steady
|
8/18/2008 | BK | Cephalon gets $200 million revolver
|
9/13/2007 | CV | Market Commentary: Countrywide stirs drink; Prudential up on rating; Cephalon sinks on drug concerns
|
4/2/2007 | CV | Market Commentary: Cephalon improves on FDA letter; Amgen remains soft on safety risks; issue pipeline seen healthy
|
12/20/2006 | CV | Cephalon exchanges $100 million of 2% convertible notes due 2015
|
12/19/2006 | CV | Cephalon exchanges $337 million of zero-coupon convertible notes
|
11/3/2006 | BT | JMP maintains Cephalon at strong buy
|
11/3/2006 | BT | Jefferies maintains Cephalon on hold
|
11/1/2006 | BT | Cephalon on hold by Jefferies
|
10/9/2006 | BT | Jefferies: CollaGenex, Forest Labs beat Q3 estimates; Connetics lags behind
|
10/4/2006 | BT | JMP keeps Cephalon at strong buy
|
9/28/2006 | BT | JMP starts coverage of Cephalon at strong buy
|
9/26/2006 | CV | Market Commentary: Advanced Medical, PMC-Sierra falls on warnings; Cephalon gains on drug nod; ChipMOS prices
|
9/26/2006 | BT | Jefferies puts Cephalon on hold
|
9/26/2006 | BT | Cephalon kept at neutral by Merrill
|
9/25/2006 | BT | Cephalon's Fentora FDA-approved for breakthrough cancer pain
|
9/18/2006 | BT | Merrill keeps Cephalon at neutral
|
8/29/2006 | BT | Jefferies updates specialty pharmaceutical market
|
8/10/2006 | BT | Jefferies puts Cephalon on hold
|
8/10/2006 | BT | Cephalon kept at neutral by Merrill
|
8/10/2006 | CV | Market Commentary: Andrew, ImClone fall on failed buyouts; BRE, Digital Realty climb on debuts; Cephalon firm as drug flops
|
8/9/2006 | BT | Cephalon to end development for ADHD drug Sparlon
|
8/4/2006 | BT | Cephalon maintained at neutral by Merrill
|
8/4/2006 | BT | Jefferies puts Cephalon on hold
|
8/2/2006 | BT | Merrill rates Cephalon at neutral
|
7/31/2006 | CV | Market Commentary: Scottish Re hit by put worries; Cephalon swings; SanDisk flat, M-Systems gains on deal; Itron solid in gray
|
7/27/2006 | BT | Jefferies keeps Cephalon at hold
|
7/26/2006 | BT | Cephalon expects second-quarter income to exceed guidance by 40%
|
7/11/2006 | BT | Merrill keeps Cephalon at neutral
|
6/30/2006 | BT | Cephalon kept at neutral by Merrill
|
6/30/2006 | BT | Jefferies keeps Cephalon on hold
|
6/30/2006 | BT | Market Commentary: Vertex soars 15% on J&J deal; Cephalon climbs over 10% on Fentora nod; Barr off slightly
|
6/30/2006 | CV | Market Commentary: Cephalon climbs on drug's progress; General Motors gains with stock; Health Management gets sweeter
|
6/29/2006 | BT | Cephalon gets approvable letter for Fentora to manage breakthrough pain
|
6/26/2006 | BT | Cephalon finds Gabitril fails to help generalized anxiety disorder
|
6/26/2006 | CV | Market Commentary: Intel, Amgen under pressure; Inco rises; Chesapeake launches mandatories offering
|
6/21/2006 | BT | Cephalon maintains neutral rating from Merrill
|
6/12/2006 | BT | Cephalon, Takeda to promote Provigil in United States
|
5/23/2006 | BT | Pharmacopeia, Cephalon to develop new therapeutic products
|
5/19/2006 | BT | Market Commentary: Illumina gains after spot sale; Neurocrine, DOV mixed; Pozen pounded; Alkermes dips, settles higher
|
5/12/2006 | BTCV | New Issue: Merrill Lynch prices $15 million 3% capped appreciation notes linked to biotech stock basket
|
5/8/2006 | BT | Jefferies specialty pharmaceuticals report
|
5/4/2006 | BT | Cephalon says fentanyl tablet reduces intensity of breakthrough pain
|
5/3/2006 | BT | Jefferies puts Cephalon on hold
|
5/3/2006 | CV | Market Commentary: Cephalon falls, PDL widens on results; NPS falls, MGI climbs on FDA news; XM firm despite lawsuits
|
5/3/2006 | BT | Cephalon held at neutral by Merrill
|
5/2/2006 | BT | Alkermes, Cephalon to make extended-release Vivitrol to treat alcoholism
|
5/2/2006 | BT | Jefferies puts Cephalon on hold
|
5/2/2006 | CV | Market Commentary: Apex Silver falls on Bolivia concerns; Quicksilver gains on earnings anticipation; Sirius up on guidance
|
5/1/2006 | BT | Cephalon receives approvable letter for Nuvigil for sleepiness
|
4/25/2006 | BT | Cephalon on hold by Jefferies
|
4/24/2006 | BT | Cephalon gets extended action date for Sparlon
|
4/19/2006 | CV | Market Commentary: ExpressJet stands firm on lost business; Gilead deal priced cheaper than talk; Cephalon gains on new data
|
4/18/2006 | BT | Cephalon tells FDA new data indicates Sparlon did not cause Stevens-Johnson syndrome
|
4/17/2006 | BT | Cephalon at hold by Jefferies
|
4/13/2006 | BT | Alkermes, Cephalon receive FDA approval of Vivitrol for treatment of alcohol dependence
|
4/4/2006 | BT | Cephalon's leukemia compound gets orphan drug status
|
3/28/2006 | BT | Cephalon granted six months of pediatric exclusivity for Provigil
|
3/28/2006 | BT | Market Commentary: Advanced Magnetics gains 7%; Xoma slides; Seattle Genetics deal surfaces; Cephalon dips 2%
|
3/27/2006 | BT | Market Commentary: Amylin drops 3% on follow-on; Keryx up 3% on PIPE; Cubist off; Cephalon off, Generex dives 20%
|
3/27/2006 | CV | Market Commentary: Lucent preferreds climb on hopes of post-merger tender; Time Warner Telecom stock upgrade boost
|
3/24/2006 | BT | Jefferies downgrades Cephalon to hold
|
3/24/2006 | BT | Merrill maintains Cephalon at neutral
|
3/24/2006 | BT | Credit Suisse maintains Cephalon at neutral
|
3/24/2006 | BT | Market Commentary: BioMarin shares, new bonds gain; Cephalon loses 13%; Idenix falls 28%; King slips; Encysive declines
|
3/24/2006 | CV | Market Commentary: Cephalon setback positive for hedged players; Lucent strengthens on merger talks; BioMarin starts strong
|
3/23/2006 | BT | Cephalon says FDA advisory committee recommends against approval of Sparlon ADHD drug
|
3/23/2006 | BT | Market Commentary: BioMarin, King deals on deck; Cephalon poised to slide Friday; CombinatoRx off on PIPE deal
|
3/23/2006 | CV | Market Commentary: BioMarin new deal gets thumbs-up; YRC weaker on poor outlook; Cephalon fails to get FDA nod
|
3/22/2006 | BT | Market Commentary: Cephalon seesaws; Nabi zooms; Endo drops; Insmed off; Elan, Biogen drop; King launches deal
|
3/22/2006 | CV | Market Commentary: General Motors rises on union deal; Cephalon see-saws on drug prospects; Interpublic cut by S&P
|
3/22/2006 | BT | Cephalon stays at neutral by Merrill
|
3/16/2006 | BT | Jefferies rates Cephalon at buy
|
3/10/2006 | CV | Market Commentary: Nortel holds firm on cross-default hopes; American Axle survives downgrade but JetBlue crashes
|
3/3/2006 | CV | Market Commentary: Intel holds up on hedged basis despite stock slide; Citigroup says convertible arbitrage paid off in February
|
2/17/2006 | BT | Market Commentary: Cytyc shares, convertibles gain big; Alkermes slips on FDA news; NPS Pharma off amid uncertainty
|
2/17/2006 | CV | Market Commentary: Citadel gains on rumors of put-seeking hedge funds; Amgen's new issues continue week's climb
|
2/16/2006 | CV | Market Commentary: Amgen convertibles active in trade; Halliburton gains; XM Satellite lower
|
2/15/2006 | BT | Jefferies boosts Cephalon to buy
|
2/15/2006 | BT | Cephalon kept at neutral by Merrill
|
2/15/2006 | CV | Market Commentary: New Amgen convertibles lift in active trade; Cephalon rises on guidance, Delta Air Lines weakens
|
2/2/2006 | CV | Market Commentary: ImClone steady despite lack of Bristol-Myers interest; Teva under pressure; Omnicare edges lower
|
2/1/2006 | BT | Cephalon says FDA extends action date on Nuvigil application to April 30
|
2/1/2006 | BT | Cephalon settles patent litigation with Barr over Provigil generic
|
1/26/2006 | BT | Merrill reiterates Cephalon at neutral
|
1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
1/25/2006 | BT | Cephalon now expects to launch Sparlon in second quarter
|
1/18/2006 | CV | Market Commentary: Techs dominate convertibles market; Intel drops outright but expands on a hedged basis, AMD adds
|
1/12/2006 | BT | Cephalon kept by Merrill at neutral
|
1/11/2006 | BT | Mylan, Cephalon form agreements for pain, CNS disorder drugs
|
1/10/2006 | BT | Cephalon settles patent litigation with Mylan over Provigil generic
|
1/10/2006 | BT | Market Commentary: ViroPharma slips; Panacos zooms; Cephalon soars on short covering; Gilead declines; Celgene retraces
|
1/10/2006 | CV | Market Commentary: LifePoint Hospitals, MGI Pharma convertibles weaker on lower guidance; Cephalon jumps; GM mixed
|
1/6/2006 | CV | Market Commentary: Convertibles market moves mostly in-line, dollar neutral; Best Buy, Cephalon gain; Affymetrix drops
|
1/4/2006 | CV | Market Commentary: Convertible market sees broad-based gains, GM, Ford lift; airlines better, Calpine adds points
|
1/3/2006 | BT | Market Commentary: Adams declines; Alkermes gains; Cephalon up; Indevus off; Wyeth up, Bradley off, ViroPharma rises
|
1/3/2006 | CV | Market Commentary: Wyeth convertibles up on pact; Cephalon adds; Mercury Interactive mostly flat
|
12/30/2005 | BT | Alkermes, Cephalon gain preliminary approval for Vivitrol from FDA
|
12/30/2005 | BT | Cephalon maintained by Merrill at neutral
|
12/23/2005 | CV | Market Commentary: Albertson's trades lower in active trade; Wyeth, Omnicare gain; GM sees light buying
|
12/22/2005 | BT | Cephalon, Ranbaxy settle patent infringement lawsuit over Provigil
|
12/22/2005 | BT | Market Commentary: AtheroGenics zooms on $1 billion pact with AstraZeneca; Regeneron rises 6%; BioCryst bounces 16%
|
12/22/2005 | CV | Market Commentary: Cephalon convertibles gain on patent agreement; SFBC up on possible sale; Albertson's, Placer lose
|
12/20/2005 | BT | Jefferies reiterates Cephalon at hold
|
12/12/2005 | BT | Cephalon says CEP-701 may help treat acute myelogenous leukemia
|
12/12/2005 | BT | Cephalon's Treanda demonstrating strong responses in clinical trials to treat non-Hodgkin's lymphoma
|
12/12/2005 | BT | Jefferies raises Cephalon price target to $53
|
12/9/2005 | CV | Market Commentary: Cephalon, Teva gain on patent settlement; eyes turn toward Omnicare; Alltel mostly quiet
|
12/9/2005 | BT | Cephalon settles patent infringement suit with Teva
|
12/9/2005 | BT | Cephalon maintained by Merrill at neutral
|
12/9/2005 | BT | Market Commentary: Adams slides after secondary; Voyager IPO delayed; Cephalon spikes, Teva rises; Genitope up
|
12/7/2005 | BT | Cephalon still neutral, Merrill says
|
12/6/2005 | BT | Market Commentary: Cephalon dips on acquisition; New River off; Ipsen prices IPO in France; Exelixis ends off highs
|
12/6/2005 | CV | Market Commentary: Kansas City Southern gains on debut; U.S. Bancorp steady after re-offer; St. Jude Medical prices
|
12/6/2005 | BT | Cephalon to acquire Zeneus for $360 million
|
12/5/2005 | BT | Cephalon's Sparlon drug improves ADHD symptoms, study says
|
12/1/2005 | BT | Bausch & Lomb signs license, research deals with Cephalon, PTC to develop treatments for blinding conditions
|
12/1/2005 | BT | Bio3, Creabilis sign research agreements with Cephalon for K252a for psoriasis, restenosis
|
11/21/2005 | BT | Merrill Lynch keeps Cephalon at neutral
|
11/15/2005 | BT | Market Commentary: Allergan bid a wrinkle in Medicis merger with Inamed; Biovail off on spinoff plan; SkyePharma up
|
11/8/2005 | CV | Market Commentary: Medtronic, Lucent, EDS, Cephalon lower in weak market; Blockbuster, Maverick, Equinix to price
|
11/7/2005 | BT | Market Commentary: Solid earnings fuel ViroPharma stock; Guidant sues Johnson & Johnson over proposed merger
|
11/7/2005 | CV | Market Commentary: Northwest, AMR higher as oil declines; Genzyme eases but Cephalon edges higher
|
11/2/2005 | BT | Market Commentary: Novavax stock slips 12.3% on $18 million direct placement; convertible biotech names mixed
|
11/2/2005 | BT | Merrill maintains Cephalon at neutral
|
11/2/2005 | BT | Jefferies keeps Cephalon at hold
|
11/1/2005 | BT | Market Commentary: Cell Therapeutics prices $82 million notes to yield 6.75%; Nabi's stock dives on failed clinical trial
|
11/1/2005 | CV | Market Commentary: Qwest, Chesapeake Energy to price $2 billion-plus in convertibles; new IPC paper trades actively
|
10/24/2005 | CV | Market Commentary: Cephalon, Reebok, Nextel Partners lose; Albertson's, Halliburton gain; Essex Partners set to price
|
10/21/2005 | BT | Merrill Lynch maintains Cephalon's neutral rating
|
10/21/2005 | BT | Cephalon gets FDA approval letter for Sparlon to treat ADHD
|
10/21/2005 | BT | Market Commentary: Electro-Optical delays IPO again; Jerini IPO scheduled for Oct. 24 week; Affymetrix off; Cephalon higher
|
10/21/2005 | BT | Market Commentary: Electro-Optical delays IPO again; Jerini IPO scheduled for Oct. 24 week; Affymetrix off; Cephalon higher
|
10/21/2005 | BT | Thomas Weisel maintains Cephalon at peer perform
|
10/17/2005 | BT | Market Commentary: Chiron falls big after closing bell; Biogen, Elan gain; Cephalon up
|
10/17/2005 | BT | Cephalon neutral rating reiterated by Merrill
|
9/21/2005 | BT | Market Commentary: Nektar, Cyberonics pitch converts; QLT spirals; Chiron players shift to 2.75s; Alkermes stumbles
|
9/20/2005 | BT | Market Commentary: Cyberonics convertible view mixed; Human Genome rises on update; Alkermes, Cephalon off on delay
|
9/20/2005 | CV | Market Commentary: US Airways, Toreador launch new deals, bringing calendar to five; Sepracor, Cephalon up
|
9/15/2005 | BT | Market Commentary: Myogen, Geron follow-ons at bat; ViroPharma up; Advancis almost doubles; GTx launches new deal
|
9/15/2005 | CV | Market Commentary: Airlines under pressure; GM, Ford mostly lower; Cephalon higher, Amgen firm
|
9/14/2005 | BT | Cephalon initiated by Rodman Renshaw at market outperform
|
9/13/2005 | BT | Market Commentary: Immunomedics up; OSI rebounds; Celgene retreats; Protein Design Labs, Novavax, Cephalon all up
|
9/6/2005 | CV | Market Commentary: Chiron trades mixed, but Curagen gains; Dobson Communications to price $150 million issue
|
9/2/2005 | BT | Cephalon maintained at neutral by Merrill
|
9/2/2005 | BT | Cephalon kept at hold by Jefferies
|
9/1/2005 | BT | Market Commentary: Chiron shares, convertibles gain on Novartis bid; Par Pharma up 1%; Cephalon up 5%, Abgenix up 9%
|
8/31/2005 | CV | Market Commentary: Moderate buying lifts convertibles of Cephalon, Micron, Maxtor; Emdeon, Mercury Interactive see interest
|
8/18/2005 | CV | Market Commentary: Six Flags selling on upswing from Snyder's move; Northwest, Delta drift higher, Charming Shoppes up
|
8/18/2005 | BT | Cephalon rated hold by Jefferies
|
8/18/2005 | BT | Market Commentary: Myogen shoots higher on trial data; Par Pharma buyers hoping for deal; Del Labs bonds fall; Cephalon up
|
8/9/2005 | BT | Cephalon initiated by Merrill at neutral
|
8/4/2005 | BT | Cephalon maintained by Jefferies at hold
|
7/12/2005 | BTCV | Cephalon to buy $511.7 million of 21/2% convertibles in tender
|
7/11/2005 | CV | Market Commentary: Northwest Airlines spurs airlines convertibles; Schlumberger extends gains; but biotech, technology ease
|
7/1/2005 | BT | Market Commentary: Altana crushed by Pfizer news; Cubist, Corixa rise in thin market, Millennium off; Cephalon higher
|
7/1/2005 | BTCV | Cephalon greenshoe exercised, pushing 2% convertibles offer to $920 million
|
6/30/2005 | CV | Market Commentary: Saks, Kodak and General Mills trade in a mixed convertibles market; June marks improvements
|
6/29/2005 | BT | Market Commentary: CV Therapeutics, Lonza upsize convertibles, both higher in trade; Millennium gains on new CEO
|
6/29/2005 | CV | Market Commentary: CV Therapeutics' new deal gains, supporting biotechs; Mirant trades in heavy volume; General Mills eases
|
6/24/2005 | BT | Market Commentary: HemoSense IPO delayed yet again; Cephalon off, Alkermes up on pact for alcoholism shot; Genentech up
|
6/24/2005 | CV | Market Commentary: Convertibles mostly extend losses a second day; biotechs waver, but some energy issues see more gains
|
6/14/2005 | CV | Market Commentary: Convertibles see more selling ahead of June redemptions; GM, Ford higher, but Calpine, Northwest sink
|
6/13/2005 | BT | Cephalon acquires cancer drug Trisenox from Cell Therapeutics in up to $170 million deal
|
6/13/2005 | CV | Market Commentary: Invitrogen launches $300 million convertible; Connetics, Cephalon stir market; Northwest hits turbulence
|
6/10/2005 | CV | Cephalon announces tender offer for 21/2% convertible subordinated notes due 2006
|
6/9/2005 | CV | Market Commentary: Calpine convertibles mixed after news whammy; market firms on fewer redemptions
|
6/6/2005 | CV | Market Commentary: Providian convertibles react flatly to Washington Mutual takeover; GM off before stockholders meet
|
6/3/2005 | CV | Market Commentary: Symmetricom prices wide, still breaks below par; Cephalon off to 98; Impax bid up; Doral eyed
|
6/2/2005 | CV | New Issue: Cephalon sells $800 million convertible at 2.0%, up 10%; hedges push premium to 60%
|
6/2/2005 | CV | Market Commentary: Cephalon suffers in aftermarket; Joy Global pulled; Symmetricom at bat; Elan retreats on drug news
|
6/1/2005 | CV | Cephalon overnight $800 million convertible talked at 1.5%-2.0%, up 10%-14%
|
6/1/2005 | CV | Market Commentary: Cephalon in overnight market; Elan bounces; Beazer better; airline paper dips
|
6/1/2005 | CV | Cephalon to tender for 21/2% convertibles with some proceeds from new deal
|
5/18/2005 | CV | Market Commentary: Xoma, deCode, Cephalon buyers seen; XM, Sirius at odds in race; Beverly auction in second round
|
5/16/2005 | CV | Market Commentary: Level 3 bonds indifferent to unit IPO; Fannie Mae bounces then retreats; TOP Tankers afloat anew
|
4/15/2005 | CV | Market Commentary: GM, Ford selling accelerates; El Paso, Calpine, NRG plunge; Ivax, Teva lose; Lucent, Tyco unwound
|
12/16/2004 | CV | Cephalon exchanges 96.5%, 98.7% of 0% convertibles
|
11/16/2004 | CV | Cephalon starts exchange for 0% convertibles
|
9/7/2004 | CV | Market Commentary: Tyco lower ahead of buybacks; Cephalon 0s fall, 2.5s steady; El Paso, Calpine higher; Valero firm
|
11/4/2003 | CV | S&P: Cephalon ratings unaffected on merger
|
10/17/2003 | CV | Market Commentary: XL holds up against stock slide on warning, boost to reserves; new Getronics euro issue zooms
|
9/25/2003 | CV | Market Commentary: Pharma Resources gains to 104 despite complaint; Bristol-Myers jumbo seen offered at par in gray
|
9/11/2003 | CV | Market Commentary: Cephalon, Tekelec bid up as players position for upsurge; airlines higher in 9/11 trading
|
9/10/2003 | CV | Market Commentary: Energy bucks downward trend; overall sentiment positive; telecoms, tech down but Level 3 up
|
8/5/2003 | CV | Market Commentary: Further cheapening noted, but many buyers waiting in wings; new deal slate remains active
|
8/4/2003 | CV | Silicon Graphics pulls exchange offer
|
6/17/2003 | CV | Cephalon to redeem 51/4% convertibles
|
6/16/2003 | CV | Market Commentary: ICOS, Lattice at bat; buzz puts Nextel Partners eyeing another convert after new junk offering
|
6/12/2003 | CV | Cephalon says $150 million greenshoe exercised, raising convertibles to $750 million
|
6/12/2003 | CV | Market Commentary: Yield-grabbers reach for busted convertibles, distressed issues; new paper mixed in secondary
|
6/11/2003 | CV | Market Commentary: Xerox emerges as a mandatory; Mirant in freefall; Tyco gains on unit sale talk; airlines fly high
|
6/10/2003 | CV | Moody's rates new IOS notes Ba1
|
6/6/2003 | CV | New Issue: Cephalon $600 million convertibles yield 0%, up 23.8% and 0%, up 17.6%
|
6/6/2003 | CV | Market Commentary: Convertibles see record week with 16 deals totaling $4.47 billion; Cephalon, Continental climb
|
6/5/2003 | CV | Cephalon $600 million two-part convertibles talked to yield 0%, up 21-26% and up 15-20%
|
6/5/2003 | CV | Market Commentary: Continental soars past 107; five new deals totaling $1.23 billion at bat after closing bell
|
5/15/2003 | CV | Cephalon buys back $7 million convertibles
|
10/2/2002 | CV | Market Commentary: Charter, EDS, El Paso, GM, others fall on plethora of ill-boding news
|
7/12/2002 | CV | Market Commentary: Market holds firm against dip in stocks as more buyers emerge
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
5/17/2002 | CV | Market Commentary: LifePoint gains in hungry market; El Paso drops on "bad" news
|
4/5/2002 | CV | Market Commentary: Adelphia gains on hiring advisors; Getty Images soars on EPS revision; Genentech falls
|
2/4/2002 | CV | Market Commentary: Convertibles plunge as stocks dive, Solutia nixes new deal
|
1/9/2002 | CV | Market Commentary: Convertibles lower on extended profit taking as new deals emerge
|
1/4/2002 | CV | Market Commentary: Convertibles higher as prospects of new deals spur activity
|
12/12/2001 | CV | Market Commentary: Convertible market broadly mixed on Enron hype, new issues,
|
12/11/2001 | CV | Cephalon says greenshoe exercised, raising convertibles to $600 million
|
12/7/2001 | CV | Market Commentary: Convertible market slides as stock enthusiasm withers, no new deals
|
12/6/2001 | CV | New Issue: Cephalon upsized $500 million convertibles at 2.5% yield, up 17%
|
12/6/2001 | CV | Market Commentary: Convertible market slips on thwarted rally in stocks; new issues mixed
|
12/5/2001 | CV | Cephalon $300 million convertibles price talk tightened to 2.5-2.75% yield, 17% premium
|
12/5/2001 | CV | Market Commentary: Convertible market roars higher as stocks rally, new deals surge
|
12/4/2001 | CV | Cephalon $300 million convertibles talked at 2.75-3.25% yield, 12-17% premium
|
12/4/2001 | CV | Market Commentary: Convertible market moves higher, gets spate of new deals lineup
|
12/3/2001 | CV | Convertible market pulls back modestly as stocks lose on Enron bankruptcy
|
11/16/2001 | CV | Cephalon exchanges $73 million convertibles for stock
|